1CHAN K C,KNOX W F,GEE J M,et al.Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast[J].Cancer Res,2002,62(1):122-128.
2ALBANELL J,ROJO F,BASELGA J.Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839[J].Semin Oncol,2001,5(Suppl 16):56-66.
3BASELGA J,AVERBUCH S D.ZD1839 (‘Ir essa’) as an anticancer agent[J].Drugs,2000,60(Suppl 1):33-40.
4MOULDER S L,YAKES F M,MUTHUSWAMY S K,et al.Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo[J].Cancer Res,2001,61(24):8887-8895.
6SWAISLAND H,LAIGHT A,STAFFORD L,et al.Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers[J].Clin Pharmacokinet,2001,40(4):297-306.
7HERBST R S,MADDOX A M,ROTHENBERG M L,et al.Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1893 is generally well-tolerated and has activity in Non-Small-Cell lung cancer and other solid tumor:results of a phase I trial[J].J Clin Oncol,2002,20(18):3815-3825.
8GIUSEPPE G,HERBST R S,MANEGOLD C,et al.Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer:a phase Ⅲ trial-INTACT1[J].J Clin Oncol,2004,22(5):777-784.
9HERBST R S,GIACCONE G,SCHILLER J H,et al.Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer a phase Ⅲ trial-INTACT2[J].J Clin Oncol,2004,2(5):785-794.
10CAPPUZZO F,ARDIZZONI A,AOTO-PARRA H,et al.Epidermal growth factor receptor targeted therapy by ZD1839(Iressa) in patients with brain metastases from non-small cell lung cancer(NSCLC)[J].Lung Cancer,2003,41 (2):227-231.
